Letermovir: Difference between revisions

Latest revision as of 10:43, 3 September 2020

Antiviral that targets subunit 2 of the viral terminase complex (UL56) in cytomegalovirus

Increases bioavailability of cyclosporine
Decreases concentration of voriconazole
Concentration of letermovir is increased by atorvastatin, sirolimus, and tacrolimus

@@ Line 1: / Line 1: @@
+== Background ==
-* Antiviral
-* Oral and intravenous
+=== Mechanism of Action ===
-* Increases bioavailability of [[cyclosporine]]
-* No renal adjustment needed
+*Antiviral that targets subunit 2 of the viral terminase complex (UL56) in [[cytomegalovirus]]
-* Indications: {{#ask: [[Is treated by::letermovir]] | default=none}}
+=== Spectrum of Activity ===
+*Indications: {{#ask: [[Is treated by::letermovir]] | default=none}}
+*No activity against [[HSV]] or [[VZV]]
+== Dosing ==
+* Letermovir 480 mg IV/PO q24h, infused over 1 hour
+* If concomitant [[cyclosporine]], decrease dose to 240 mg IV/PO q24h
+=== Renal Dosing ===
+* No dose adjustment needed as long as CrCl >10 mL/min
+== Safety ==
+=== Adverse Drug Reaction ===
+* Nausea, vomiting, diarrhea, cough, headache, peripheral edema
+=== Drug-Drug Interactions ===
+*Increases bioavailability of [[cyclosporine]]
+*Decreases concentration of [[voriconazole]]
+*Concentration of letermovir is increased by [[atorvastatin]], [[sirolimus]], and [[tacrolimus]]
 [[Category:Antivirals]]